Publications
Detailed Information
Allelic variants of CD40 and CD40L genes interact to promote antibiotic-induced cutaneous allergic reactions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sae-H | - |
dc.contributor.author | Lee, J-E | - |
dc.contributor.author | Kim, Sang-H | - |
dc.contributor.author | Jee, Y-K | - |
dc.contributor.author | Park, H-S | - |
dc.contributor.author | Park, H-W | - |
dc.contributor.author | Min, K-U | - |
dc.contributor.author | Kim, Y-K | - |
dc.date.accessioned | 2012-05-23T04:26:02Z | - |
dc.date.available | 2012-05-23T04:26:02Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | CLINICAL AND EXPERIMENTAL ALLERGY; Vol.39 12; 1852-1856 | ko_KR |
dc.identifier.issn | 0954-7894 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76318 | - |
dc.description.abstract | P>Background The danger hypothesis provides a new perspective of the mechanisms underlying drug allergy. In this study, we evaluated associations between variations in the genes involved in danger signal pathways and antibiotic-induced cutaneous allergic reactions (AICARs). Methods Two hundred cases with urticaria, angio-oedema, maculopapular rash, and erythema multiforme caused by antibiotics were extracted from the database of the Adverse Drug Reaction Research Group in Korea. All cases were confirmed by an allergy specialist. Causative antibiotics included penicillin, cephalosporin, quinolone, and others (approximately 40 different types). Ten single nucleotide polymorphisms (SNPs) in seven genes (-318C > T, +49A > G, and +6230G > A in CTLA4, IVS+17T > C in CD28, -3479T > G and I170V in CD86, -1C > T in CD40, -3458A > G in CD40LG, -308G > A in TNF, and -31T > C in IL1B) were scored for cases and for healthy subjects without a history of AICARs. Results Our analysis failed to reveal differences in the distribution of the 10 SNPs between cases and controls. However, we could find a gene-gene interaction between -1C > T in CD40 and -3458A > G in CD40L using multifactor dimensionality reduction analysis. Subjects with minor alleles of both SNPs showed a significant risk for developing AICARs [P=0.017, odds ratio (OR) (95% confidence interval)=2.93 (1.20-7.97)]. Conclusion Our findings suggest that a genetic interaction between CD40 and CD40L favours the development of AICARs. Cite this as: Sae-H Kim, J-E Lee, Sang-H Kim, Y-K Jee, Y-K Kim, H-S Park, K-U Min, H-W Park and The Adverse Drug Reaction Research Group in Korea, Clinical & Experimental Allergy, 2009 (39) 1852-1856. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | antibiotics | ko_KR |
dc.subject | drug hypersensitivity | ko_KR |
dc.subject | CD40 | ko_KR |
dc.subject | CD40 ligand | ko_KR |
dc.title | Allelic variants of CD40 and CD40L genes interact to promote antibiotic-induced cutaneous allergic reactions | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1111/j.1365-2222.2009.03336.x | - |
dc.citation.journaltitle | CLINICAL AND EXPERIMENTAL ALLERGY | - |
dc.description.citedreference | Park HW, 2007, CLIN EXP ALLERGY, V37, P1609, DOI 10.1111/j.1365-2222.2007.02820.x | - |
dc.description.citedreference | Motsinger AA, 2007, PHARMACOGENOMICS, V8, P1229, DOI 10.2217/14622416.8.9.1229 | - |
dc.description.citedreference | Posadas SJ, 2007, CLIN EXP ALLERGY, V37, P989 | - |
dc.description.citedreference | Sanderson JP, 2007, J IMMUNOL, V178, P5533 | - |
dc.description.citedreference | Park JH, 2007, AM J RESP CRIT CARE, V175, P775, DOI 10.1164/rccm.200609-1286OC | - |
dc.description.citedreference | Valeyrie-Allanore L, 2007, DRUG SAFETY, V30, P1011 | - |
dc.description.citedreference | Malarstig A, 2006, ARTERIOSCL THROM VAS, V26, P1667, DOI 10.1161/01.ATV.0000222908.78873.36 | - |
dc.description.citedreference | Caproni M, 2006, BRIT J DERMATOL, V154, P319, DOI 10.1111/j.1365-2133.2005.07023.x | - |
dc.description.citedreference | Uetrecht J, 2005, TOXICOLOGY, V209, P113, DOI 10.1016/j.tox.2004.12.019 | - |
dc.description.citedreference | Aiba S, 2003, J INVEST DERMATOL, V120, P390 | - |
dc.description.citedreference | SEGUIN B, 2003, CURR OPIN ALLERGY CL, V3, P235 | - |
dc.description.citedreference | Pirmohamed M, 2002, TOXICOLOGY, V181, P55 | - |
dc.description.citedreference | Barker RN, 2002, CLIN EXP IMMUNOL, V127, P220 | - |
dc.description.citedreference | Gruchalla RS, 2001, J ALLERGY CLIN IMMUN, V108, P475, DOI 10.1067/mai.2001.118509 | - |
dc.description.citedreference | Arrighi JF, 2001, J IMMUNOL, V166, P3837 | - |
dc.description.citedreference | Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114 | - |
dc.description.citedreference | Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590 | - |
dc.description.citedreference | Sauter B, 2000, J EXP MED, V191, P423 | - |
dc.description.citedreference | Gallucci S, 1999, NAT MED, V5, P1249 | - |
dc.description.citedreference | Uetrecht JP, 1999, CHEM RES TOXICOL, V12, P387 | - |
dc.description.citedreference | Curtsinger JM, 1999, J IMMUNOL, V162, P3256 | - |
dc.description.citedreference | MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991 | - |
dc.description.citedreference | JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11 | - |
dc.description.citedreference | FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185 | - |
dc.description.citedreference | MEYERS DG, 1985, AM HEART J, V109, P1393 | - |
dc.description.citedreference | PULLEN H, 1967, LANCET, V2, P1176 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.